Importantly, we observed that the mTOR pathway was significantly enriched in KRAS mutant cells, and the in-silico analyses indicated a significant association between mTOR overexpression and worse overall survival in NSCLC patients. Here, MTOR is linked to non-small cell lung carcinoma.